Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Marcus Carvalho Borin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Medicines and Pharmaceutical Assistance, Department of Social Pharmacy, Faculty of Pharmacy, Federal University of Minas Gera…. Hauptthemen laut MEDLINE: Gaucher Disease, Drug Costs. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Gaucher disease (GD) requires lifelong high‐cost treatment within the Brazilian Unified Health System (SUS). In Brazil, treatment eligibility and monitoring are defined by Clinical Protocol and Therapeutic Guidelines (PCDT), while pharmaceutical prices are regulated by the Drug Market Regulation Chamber (CMED). Exploratory price–value approaches may help make explicit the relationship between drug prices and measurable clinical benefit. We explored the applicability of a Pareto‐based Efficiency Frontier (EF) as a descriptive hematologic price–value framework for GD therapies in Brazil.
Methods
An exploratory Pareto‐based EF analysis compared annual drug acquisition prices with standardized hematologic benefits, defined as hemoglobin and platelet improvements, derived from a published systematic review. Annual prices were obtained from CMED, Maximum Price of Sale to the Government (PMVG), and median public procurement prices from the Health Price Database (BPS). Prices are presented in Brazilian reais and USD adjusted by purchasing power parity. Directly dominated technologies were excluded, and all remaining directly non‐dominated therapies were connected by linear interpolation to form a Pareto‐based 12‐month reference EF. This construction retains alternatives that would be excluded by extended dominance under a conventional convex EF. The analysis was restricted to treatment‐naïve patients.
Results
Annual costs ranged from approximately USD‐PPP 94900 to 763 200. Under the primary 12‐month analysis, imiglucerase was directly dominated across all three pricing scenarios, whereas taliglucerase alfa, velaglucerase alfa, and miglustat defined the Pareto‐based frontier. In the BPS hemoglobin analysis and in all three platelet analyses, taliglucerase alfa would be subject to extended dominance under a conventional convex EF but was retained as a directly non‐dominated therapy. This classification was conditional on indirect comparisons from heterogeneous evidence and the selected 12‐month hematologic point estimates. In the descriptive scenario analysis, direct dominance of imiglucerase was less stable when maximum effects across longer follow‐up durations were considered.
Conclusion
This exploratory application of a Pareto‐based Efficiency Frontier describes the relationship between current price scenarios and comparative hematologic benefit for GD therapies. Findings should not be interpreted as definitive comparative value evidence, an ICER‐based optimization rule, or a stand‐alone pricing instrument. The approach may complement broader value‐based assessment alongside QALY‐based modeling, long‐term outcomes, formal uncertainty analysis, and non‐hematologic clinical dimensions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Program in Medicines and Pharmaceutical Assistance, Department of Social Pharmacy, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Collaborating Center for Health Technology Assessment and Excellence in Health, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Division of Biological and Life Sciences, Visiting Associate Professor of Epidemiology, Mohamed Bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.
ORCID-Profile: Marcus Carvalho Borin, Ludmila Peres Gargano, Juliana Álvares-Teodoro, Augusto Afonso Guerra
Zitieren
APA
Borin, M. C., Gargano, L. P., Acurcio, F. A., Álvares-Teodoro, J., & Guerra, A. A. (2026). Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70497
Vancouver
Borin MC, Gargano LP, Acurcio FA, Álvares-Teodoro J, Guerra AA. Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70497
BibTeX
@article{Borin2026,
author = {Borin, Marcus Carvalho and Gargano, Ludmila Peres and Acurcio, Francisco de Assis and Álvares-Teodoro, Juliana and Guerra, Augusto Afonso},
title = {Applying a Pareto‐Based Efficiency Frontier to Inform Value‐Based Pricing for Gaucher Disease Therapies in Brazil},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70497}
}
EUVIMED